\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesThe EuroHPC Joint Undertaking has adopted an update to its 2026 Work Programme, securing funding for AI Gigafactories and clarifying the conditions for its allocation.
Funding for the AI Gigafactories will combine EU funding, contributions from participating countries, and private investments. EU financial support comes from three EU programmes: Digital Europe Programme, Horizon Europe and Connecting Europe Facility - Digital.
The planned EU contribution amounts to €1 billion in total and is expected to cover 17% of the estimated construction costs of the AI Gigafactories.
The next steps expected include securing funding commitments from interested countries, joint procurement by EuroHPC JU and participating countries to select the best offers, and signing hosting agreements with selected consortia.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health EIT AI Continent Deployment: Best use of technologies
EIT Health’s Innovation Uptake Call focuses on mature digital, data-driven and AI-powered solutions and seeks to support the last steps towards commercialisation. Applicants must apply as a consortium of at least two independent legal entities from different countries. The consortium must include partners from at least two sides of the Knowl... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
